硼替佐米联合地塞米松和沙利度胺治疗初治多发性骨髓瘤的临床效果

目的探讨硼替佐米联合地塞米松和沙利度胺(VTD)治疗初治多发性骨髓瘤(MM)的临床效果。方法选取我院2015年4月至2017年8月收治的50例初治MM患者作为研究对象,按照化疗方案的不同将其分为试验组(25例,VTD方案)和对照组(25例,传统化疗方案)。比较两组患者的治疗效果及不良反应发生情况。结果随访1~2年,试验组的治疗总有效率为76.0%,明显高于对照组的48.0%(P<0.05)。患者用药期间不良反应以乏力、血小板计数降低、腹泻、阵发性房颤等为主,经对症处理后均基本缓解,两组的不良反应总发生率比较,差异不显著(P>0.05)。结论 VTD方案治疗MM的临床效果显著,可缓解患者症状,且安全性较高,可作为初治MM患者的首选化疗方案。

Clinical effect of bortezomib combined with dexamethasone and thalidomide in the treatment of primary multiple myeloma

Objective To explore the clinical effect of bortezomib combined with dexamethasone and thalidomide(VTD)in the treatment of primary multiple myeloma(MM). Methods A total of 50 patients with primary MM admitted in our hospital from April 2015 to August 2017 were selected as the research objects and divided into experimental group(25 cases, VTD scheme) and control group(25 cases, traditional chemotherapy scheme) according to the different chemotherapy schemes. The therapeutic effect and adverse reactions of the two groups were compared. Results After 1-2 years follow-up,the total effective rate of treatment in the experimental group was 76.0%, which was significantly higher than 48.0% in the control group(P<0.05). The main adverse reactions during medication were asthenia, decreased platelet count, diarrhea and paroxysmal atrial fibrillation, which were basically alleviated after symptomatic treatment, and there was no significant difference in the total incidence of adverse reactions between the two groups(P >0.05). Conclusion VTD scheme in the treatment of MM has a significant clinical effect, it can alleviate the symptoms of patients, has a higher safety, and can be used as the first choice chemotherapy scheme for the primary MM patients.